Effects of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator inhibitor type 1, tissue plasminogen activator, fibrinogen and insulin

被引:7
|
作者
Carmichael, AR
Tate, G
King, RFG
Sue-Ling, HM
Johnston, D
机构
[1] Leeds Gen Infirm, Acad Dept Surg, Leeds, W Yorkshire, England
[2] Leeds Gen Infirm, Dept Haematol, Leeds, W Yorkshire, England
关键词
obesity; fibrinolysis; fibrinogen; insulin;
D O I
10.1159/000057287
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (t-PA), fibrinogen and insulin were measured in 43 patients 3 years after they had undergone the Magenstrasse and Mill (MM) procedure and in 43 morbidly obese (MO) patients. Mean plasma PAI-1 was 61 ng/ml in the MO group compared to 30 ng/ml in the MM group (p < 0.0001); mean plasma t-PA was 10 ng/ml in the MO group compared to 7 ng/ml in the MM group (p < 0.001). Mean fibrinogen was 3.6 g/l in the MO group compared to 3.2 g/l in the MM group (p < 0.05). Mean plasma insulin levels were 32 U/ml in the MO group compared to 15 U/ml in the MM group. These changes suggest that use of the MM procedure may reduce mortality and morbidity from coronary heart disease in these high-risk obese patients. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:40 / 43
页数:4
相关论文
共 50 条
  • [1] Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity
    Bastard, JP
    Piéroni, L
    BIOMEDICINE & PHARMACOTHERAPY, 1999, 53 (10) : 455 - 461
  • [2] Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
    Johansson, L
    Jansson, JH
    Boman, K
    Nilsson, TK
    Stegmayr, B
    Hallmans, G
    STROKE, 2000, 31 (01) : 26 - 32
  • [3] Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator
    Bjorquist, P
    Ehnebom, J
    Inghardt, T
    Deinum, J
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1997, 1341 (01): : 87 - 98
  • [4] Haemostatic factors and risk of coronary artery disease - Fibrinogen, tissue plasminogen activator and plasminogen activator inhibitor 1
    Kirschstein, W
    Scherhag, A
    Staedt, U
    Dempfle, CE
    Keller, H
    MEDIZINISCHE WELT, 1996, 47 (09): : 385 - 393
  • [5] POSTOPERATIVE CHANGES IN PLASMA TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR
    AOKI, K
    NISHINO, N
    BABA, S
    URANO, T
    TAKADA, A
    SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 1994, 24 (12): : 1039 - 1043
  • [6] Tissue plasminogen activator and plasminogen activator inhibitors of type 1 and type 2 in the plasma of parturient women
    Uszynski, M
    Uszynski, W
    Zekanowska, E
    Garbacz, J
    Kielkowski, A
    Marcinkowski, Z
    JOURNAL OF PERINATAL MEDICINE, 1996, 24 (04) : 339 - 345
  • [7] Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients
    Lindgren, A
    Lindoff, C
    Norrving, B
    Astedt, B
    Johansson, BB
    STROKE, 1996, 27 (06) : 1066 - 1071
  • [8] Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen - Effect of dieting with or without exercise in overweight postmenopausal women
    Svendsen, OL
    Hassager, C
    Christiansen, C
    Nielsen, JD
    Winther, K
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (03) : 381 - 385
  • [9] Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile
    Lee, SJ
    Cho, JS
    Chung, JP
    Lee, KS
    Chung, JB
    Lee, SI
    Moon, YM
    Kang, JK
    Kwon, SW
    Chi, HS
    Choi, JR
    Song, KS
    YONSEI MEDICAL JOURNAL, 2000, 41 (01) : 119 - 122
  • [10] Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study
    Simpson, AJ
    Booth, NA
    Moore, NR
    Lewis, SJ
    Gray, RS
    ACTA DIABETOLOGICA, 1999, 36 (03) : 155 - 158